Combination of canagliflozin and adagrasib as a novel targeted therapy for LKB1-KRASG12C co-mutated NSCLC

Cancer Letters · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles